Published by Abigail Townsend on 16th July 2025
(Sharecast News) - An investigational AstraZeneca treatment for amyloidosis has failed to show a statistical significance in late-stage trials, the blue chip pharmaceutical group said on Wednesday.
URL: http://www.digitallook.com/dl/news/story/35220266/...